( ormation on trials please visit

Notes to Editors

PROMACTA(R) is the proposed registered trademark of the GlaxoSmithKline group of companies to be used in the United States.

    To access the latest GSK news, visit http://us.gsk.com/.



    US Media enquiries:              Jeff McLaughlin    1 919 483 2839


                                     Mary Anne Rhyne    1 919 483 2839



    US Analyst/ Investor             Frank Murdolo      1 215 751 7002

    enquiries:

                                     Tom Curry          1 215 751 5419



    REFERENCES


    (1)  Bussel, J., Provan A., Shamsi T et al. Eltrombopag Raises Platelet

         Count and Reduces Bleeding compared with Placebo during

         Short-term Treatment in Chronic Idiopathic Thrombocytopenic Purpura:

         A Phase III Study. Presented 9th June 2007, 12th Congress of the

         European Hematology Association, Vienna, Austria.

    (2)  Cines DB, McMillan R. Management of adult idiopathic thrombocytopenic

         purpura. Annu Rev Med. 2005;56:425-442.

    (3)  Cohen, YC., Djulbegovic B., et al.  The bleeding risk and natural

         history of idiopathic thrombocytopenic purpura in patients with

         persistent low platelet counts. Arch Int Med. 2000:160 (11);1630-8.

    (4)  Bussel, J., Cheng, G. et al.  Analysis of Bleeding in Patients with

         Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind,

         Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth

         Factor. Presented 11 December 2006, 48th Annual Meeting of the

         American Society of Hematology, Orlando, Florida, USA -

         - Abstract #475.

    (5)  htt
'"/>




Page: 1 2 3 4 5 6 
Related medicine technology :

1. NexMed Announces Completion of Patient Enrollment in Two Pivotal
Phase 3 Studies for Anti-Fungal Product
2. Advanced Life Sciences Announces Supplemental Efficacy Data from
First Pivotal Phase 3 Pneumonia Clinical Trial
3. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable
Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical
Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
4. Accentia Biopharmaceuticals Announces Favorable Interim Blinded
Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial
for Chronic Sinusitis
5. Novagali Pharma Presents at AACO the Results of its Pivotal Phase
III Clinical Trial of Vekacia in Children Suffering From Vernal
Keratoconjunctivitis
6. Cethromycin Achieves Primary Endpoint in Pivotal Phase 3 Pneumonia
Clinical Trial
7. Javelin Pharmaceuticals Announces Successful Pivotal Phase 3 Trial
Data
8. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial as Compared to Neostigmine
9. Organons Sugammadex Demonstrated a 9-12 Times Faster Recovery in
Phase III Pivotal Trial Compared to Neostigmine
10. Updated Overall Survival Data From Pivotal Herceptin Adjuvant
Studies in HER2-Positive Breast Cancer
11. GenVec Announces Update of Safety and Efficacy Data from Pivotal
Phase II/III PACT Study of TNFerade at ASCO